BioSpace News Archive

Endonovo Therapeutics, Inc. named Ira Weisberg as President and Chief Commercial Officer of its Medical Division.

Melinta Therapeutics, LLC, a commercial-stage company providing innovative patient care therapies for acute and life-threatening illnesses, is partnering with OptimizeRx Corp. in an Innovate4Outcomes event - a healthcare design thinking-inspired event.

Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the pricing of an underwritten public offering of 6,700,000 shares of its common stock at a price to the public of $12.00 per share.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share.

IVERIC bio, Inc., announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions.

The Menarini Group will present additional data from the Phase 3 EMERALD study (NCT03778931) of elacestrant, an investigational oral SERD, during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10.

Acer Therapeutics Inc. announced that it has entered into definitive agreements with its CEO as well as its Chairman for a private placement of its securities for gross proceeds of $1.5 million.

OncoSec Medical Incorporated announced the pricing of its “reasonable best efforts” public offering of 1,166,667 shares of common stock and Common Warrants to purchase 1,166,667 shares of common stock at a combined price of $3.00 per share, for aggregate gross proceeds of $3.5 million, before deducting placement agent fees and other offering expenses.